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Abstract 
The efficacy of Org 2766, an ACTH(4-9) analogue, on the recovery of cisplatin neuropathy of longstanding duration was 
investigated in a phase II study. Twenty-two patients were treated with Org 2766 during a period of 4 months and vibration perception 
threshold (VPT) and sum scores for neuropathic symptoms and signs were compared with pre-treatment values. No change in VPT 
could be detected. Although there was a small improvement of clinical measures for neuropathy, no clear evidence for repair could 
be obtained. These results indicate no beneficial effect of Org 2766 on recovery of a longstanding cisplatin neuropathy. 
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1. Introduction 
Cisplatin is an effectiw~ cytotoxic agent in the treat- 
ment of various malignancies, including ovarian, testicu- 
lar and bladder cancer. Since the use of vigorous hydra- 
tion to reduce nephrotoxicity, peripheral neuropathy is
considered the dose-limiting side effect of Cisplatin [1]. 
This neuropathy is characterized by a pure sensory poly- 
neuropathy caused by damage of large myelinated fibers, 
possible at the level of the dorsal root ganglion [2]. Pa- 
tients suffer from paresthesias, numbness, loss of tendon 
reflexes and a decrease in mainly thick-fiber mediated 
sensory qualities as vibration sense, fine touch percep- 
tion and proprioception. In some patients a disabling 
sensory ataxia may develop [2-5]. The neuropathy may 
continue to deteriorate during a period of one to four 
months after cessation of treatment, followed by a grad- 
ual but incomplete improvement between four to twelve 
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months thereafter [6]. In one large prospective study the 
overall incidence of polyneuropathy was 47% after a 
median cumulative cisplatin dose of 500-600 mg/m 2and 
in only about 50% of patients, a complete recovery was 
observed [3]. 
Melanocortins, uch as ACTH and melanocyte-stimu- 
lating hormone-like peptides, enhance peripheral nerve 
repair. The ACTH(4-9) analogue Org 2766 has demon- 
strated neurotrophic properties, but no corticotrophic or 
melanotrophic activity [7]. The ability of Org 2766 to 
counteract the neurotoxic side effects of cisplatin has 
been investigated in animal and human studies [7-12]. In 
a rat model it was demonstrated that Org 2766 could 
prevent cisplatin-induced reduction of sensory nerve 
conduction velocities, without compromising antitumor 
activity [8]. In a subsequent double-blind, placebo-con- 
trolled study in 55 patients with ovarian cancer, these 
results could be confirmed. Concomitant treatment with 
Org 2766 prevented the occurrence of neuropathy as 
determined by 'vibration perception threshold' (VPT) as 
well as for neurological signs and symptoms [9]. 
Presently, it is unclear whether Org 2766 can also 
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improve an already established cisplatin neuropathy. 
One study in rats has shown that Org 2766 did not accel- 
erate the recovery from an existing cisplatin europathy 
[10]. To address this issue in humans, we studied the 
effect of Org 2766 in patients with a longstanding cis- 
platin neuropathy of at least one year duration. 
2. Material and methods 
This study had a prospective and open design. Patients 
with cisplatin-induced polyneuropathy consisting of clin- 
ical symptoms and signs and an increased VPT with at 
least a value of 1.00 /2m (normal: 0.30 + 0.25 /2m, 
mean + SD) and a cisplatin free interval of more than 
1 year were eligible. Life expectancy had to be more than 
6 months. All patients gave their informed consent. Pa- 
tients with diabetes mellitus, alcohol abuse, other neuro- 
logical disease and recent use of vitamin preparations 
were excluded. Patients enrolled in previous Org 2766 
studies were also excluded from the study. 
Treatment consisted of a dose of 2 mg Org 2766 s.c. 
administered 3 times a week for 4 months. The severity 
of neuropathy was evaluated by a questionnaire for neu- 
rological symptoms, by sensory neurological testing and 
by assessment of VPT. Measurements were performed at 
the start of treatment, monthly during the first half year, 
every 2 months the next half year, and at 18 months after 
the start of treatment with Org 2766. The questionnaire 
enquired separately the absence (0) or presence (1) of 
paresthesias, numbness, loss of dexterity, unsteadiness of 
gait, Lhermitte sign and pain. On sensory examination 
various tests including position sense, vibration sense, 
pinprick sensation, Romberg sign, Romberg with heel- 
to-toe stand and tight rope walking were scored as nor- 
mal (0) or abnormal (1). A sum score for these symptoms 
and signs was calculated (min 0, max 12). Two-point 
discrimination on the dorsal hand (interval 1.5, 3, 5 and 
10 cm) and on the distal tibia (interval 4 and 10 cm) was 
measured, and scored as normal (0) or abnormal (1) per 
interval. A discrimination-sense score was calculated 
(min 0, max 6). VPT was measured at the dorsum of the 
second metacarpal bone of the left hand with a Vibrame- 
Table 1 
Vibration perception threshold (VPT in/lm), sum score and discrimina- 
tion-sense score in patients treated with Org 2766. Values are mean 
(+ SD). 
Months since n VPT a Sum score Discrimination- 
start treatment sense score 
0 22 3.1 (+ 2.8) 6.8 (+2.7) 3.3 (+ 1.5) 
6 22 2.7 (_+2.5) 7.2 (+2.0) 2.4 (+ 1.0) 
12 14 2.6 (+2.7) 6.4 (+2.6) 2.1 (+ 1.3) 
18 14 3.3 (+2.4) 6.1 (+2.1) 2.1 (+0.9) 
a4 patients with pretreatment VPT regarded as outliers are excluded 
from calculation. 
ter type III (Somedic AB, Stockholm, Sweden) and re- 
corded in ~tm of skin displacement. The Vibrameter uses 
a vibratory frequency of 100 Hz and corrects for pres- 
sure-induced alterations in vibratory amplitude. The 
method of limits was used to obtain the mean VPT which 
was repeated 3 times. This method has been shown to be 
sensitive and reproducible [13]. 
On average ight complete valuations were obtained 
per patient. Linear regression analysis was applied by 
which for each patient the natural logarithm of VPT, the 
sum score and the discrimination-sense score were fitted 
against ime. From the fitted lines the change over a 
period of one year for each of these three parameters was 
calculated. These values were used to calculate Spear- 
man rank correlation coefficients between these parame- 
ters and to test whether any of these changes were statis- 
tically significantly different from 0, using the Wilcoxon 
signed rank test. 
3. Results 
A total of 22 patients (7 males, 15 females) were en- 
tered into the study. The mean age was 57 years (range 
32-74 years). Primary tumor was ovarian cancer in 15, 
melanoma in 1, and testicular cancer in 6 patients. The 
median cumulative cisplatin dose patients had received 
was 575 mg/m z(range 375-900 mg/m2). The median time 
interval between the last cisplatin administration and 
start of therapy was 4 years (range 1-9 years). Fourteen 
patients had been treated by combination chemotherapy, 
9 including hexamethylmelamine (median dose 15.7 
g]m 2, range 9.8-45.6), 3 including vincristine (6, 12 and 
14 mg/m 2) and 2 including vinblastine (80 and 90 mg/m2). 
All 22 patients could be followed until 6 months and 
14 patients until 18 months after treatment. Three pa- 
tients reported a subjective improvement and one patient 
a deterioration fsymptoms after 6 months of treatment. 
One patient had stopped therapy with Org 2766 after 
2 months for psychological reasons. No adverse ffects 
of Org 2766 were observed. 
Table 1 shows the mean VPT, mean sum score and 
mean discrimination-sense score before start of treat- 
ment and during follow up. Four patients howed ex- 
tremely high VPT values before treatment with substan- 
tially lower values at subsequent measurements, which 
Table 2 
One-year change in log VPT, sum score and discrimination sense-score" 
Mean (+_ SD) p value 
log VPT -0.02 (_+ 0.47) b 0.41 
Sum score -0.90 (_+ 1.76) 0.046 
Discrimination-sense score - 1.11 (+ 1.06) 0.0004 
aCalculated from linear regressions. 
bEquivalent to a relative decrease in VPT of 8%. 
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were not accompanied by similar changes in the sum 
score and discrimination-.sense score. These 4 pretreat- 
ment VPT values were regarded as outliers and excluded 
from the calculations oJ~ the mean VPT and 1-year 
change in log VPT. 
Table 2 shows the mean values for the fitted one-year 
change in log VPT, sum score and discrimination-sense 
score. It shows a statistically significant decrease of ap- 
proximately 1point for both sum score and discrimina- 
tion-sense score. There was no significant decrease in 
VPT. Furthermore, there was no evidence of a clear 
positive association betwe, en the 1-year changes of these 
parameters (Spearman rank correlations between -0.22 
and +0.16). 
4. Discussion 
The results of the present study indicate no clear ben- 
eficial effect of Org 2766 on a cisplatin-induced neuropa- 
thy of I year duration or more. Gerritsen van der Hoop 
et al. [9] showed that Org 2766, when given concomi- 
tantly with cisplatin, can prevent or attenuate an increase 
in VPT and sum score for neuropathic symptoms and 
signs. The same measurements were used in the present 
study, together with a score for discrimination-sense 
which was added as a third neuropathy-parameter. The 
VPT has been demonstrated to be a reliable and quanti- 
tatively valid indicator of cisplatin neuropathy [4,14]. 
The VPT did not show a significant decrease following 
treatment with Org 2766. Both the sum score for symp- 
toms and signs and the discrimination-sense core 
showed some improvement which however was so small, 
that we would consider this clinically irrelevant. 
These results are in agreement with a previous study 
in a rat model that could not demonstrate acceleration 
of recovery of an existing cisplatin neuropathy by Org 
2766 [10]. It has been suggested that melanocortins, such 
as Org 2766, mimic or amplify an endogenous signal that 
operates in the regenerative response of the damaged 
nerve. Observations in animal studies that Org 2766 is 
only active in the early phase of nerve regeneration, may 
explain the failure of this peptide to enhance recovery in 
longstanding cisplatin neuropathy [7,11]. After about 8 
days following nerve injury no further effect on regener- 
ation could be detected in the rat [7]. Apparently, en- 
hancement of nerve repair by Org 2766 seems to be 
limited to a critical early period after nerve damage. 
We conclude that this study indicates no efficacy of 
Org 2766 on the recovery of a longstanding cisplatin- 
induced neuropathy. In the prevention of cisplatin neu- 
ropathy, Org 2766 seems beneficial only when adminis- 
tered concomitantly with cisplatin. 
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